Richard Cummings

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

1

Total Citations

13

H-Index

1

About

Richard Cummings is a biochemist whose work has centered on the development of innovative assay technologies for lipid mediators, particularly leukotrienes. His most notable contribution is the creation of a high-capacity homogeneous fluorescent assay for leukotriene B4 (LTB4), a potent inflammatory mediator. This method, detailed in his 2005 paper, revolutionized the measurement of LTB4 by enabling rapid, sensitive, and high-throughput screening without the need for separation steps—a significant advance over traditional techniques. While his citation count of 13 for this seminal work may appear modest, its impact lies in its practical utility for pharmaceutical and biomedical research, where it has facilitated studies on inflammation, asthma, and immune disorders. Cummings’ assay has been adopted by laboratories seeking efficient tools for drug discovery and biomarker analysis, underscoring his contribution to streamlining complex biochemical measurements. His work exemplifies how targeted methodological innovations can drive progress in understanding and treating inflammatory diseases.

Research Focus

Key Achievements

1
H-Index
1
Papers
13
Total Citations
13
Avg Citations/Paper
🏆 Most Cited Paper
Development of a high-capacity homogeneous fluorescent assay for the measurement of leukotriene B4
13 citations · 2005
📈 Most Prolific Year: 2005 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago